Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

125P - Preliminary analysis on safety of the DEDALUS phase II trial: Induction chemo-durvalumab followed by reduced-dose radiotherapy and maintenance durvalumab for patients with unresectable stage III NSCLC

Date

22 Mar 2024

Session

Poster Display session

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Andrea Riccardo Filippi

Citation

Annals of Oncology (2024) 9 (suppl_3): 1-10. 10.1016/esmoop/esmoop102570

Authors

A.R. Filippi1, J. Saddi2, F. Agustoni3, D.L. Cortinovis4, S. Arcangeli5, G. Galli3, G.M. Stella3, D. Cicognini3, A. Ferrari3, C. Klersy3, P. Pedrazzoli3, U. Malapelle6, F. Grossi7

Author affiliations

  • 1 Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan/IT
  • 2 Fondazione IRCCS Policlinico SAN MATTEO, Pavia/IT
  • 3 Fondazione IRCCS Policlinico San Matteo, Pavia/IT
  • 4 SC Oncologia Medica ASST H S Gerardo, Monza/IT
  • 5 SC Radioterapia IRCCS San Gerardo dei Tintori, Monza, Italy; Università degli Studi Milano-Bicocca, Milan/IT
  • 6 Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, Napoli/IT
  • 7 University of Insubria, Varese/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 125P

Background

In this phase II, single-arm study, patients with stage III unresectable NSCLC deemed not eligible for concurrent chemoradiotherapy (CRT) by a MDT are treated with induction chemo-immunotherapy followed by de-intensified, hypo-fractionated radiotherapy (RT) plus durvalumab, followed by durvalumab maintenance. This report presents a pre-planned, interim safety analysis.

Methods

Patients with tumors with any PD-L1 expression, EGFR/ALK-negative, were eligible. After 3 cycles of CT-durvalumab, responders (SD, CR, PR) received hypo-fractionated thoracic RT (45 Gy over three weeks) with concurrent durvalumab, followed by durvalumab maintenance for up to 12 months or until progression. The primary endpoint was safety, defined as the incidence of possibly related adverse events (PRAES) within the first six months from the first durvalumab dose. Benchmark comparison will be made with PACIFIC-6 safety and efficacy, using identical inclusion/exclusion criteria.

Results

The first patient was screened in February 2022. At the time of data extraction, 21 pts were screened, and 20 enrolled across 3 Italian Centers. Baseline features: median age of 71 (51-84 yrs); 11 male, and 9 females. All were smokers, 8 with squamous, and 12 non-squamous histology; 4 stage IIIA, 13 IIIB, 3 IIIC; PD-L1 was negative in 7, 1-49% in 6, and ≥ 50% in 5 (2 not available). Two pts (10%) had grade 3/4 PRAES, during the induction phase (two neutropenia with sepsis), leading to permanent interruption. Two additional pts had grade 3 serious adverse events unrelated to treatment but leading to discontinuation. We observed 5 disease progressions (1 during induction, 2 before RT, 1 post-RT, and 1 during maintenance). Nine pts are still on treatment, without recorded PRAES. Two pts are in follow-up.

Conclusions

This preliminary safety analysis supports the feasibility and tolerability of the DEDALUS sequence. The trial will continue enrolling patients, also collecting longitudinal blood samples for ctDNA measurement baseline, after CRT and at progression.

Clinical trial identification

NCT05128630.

Legal entity responsible for the study

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Funding

AstraZeneca.

Disclosure

A.R. Filippi: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche; Financial Interests, Personal, Invited Speaker: AstraZeneca, Ipsen, Takeda, AstraZeneca; Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Invited Speaker: AstraZeneca, MSD; Financial Interests, Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.